AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05000983
Drug: PluroGel
RxNorm normalized name: PLUROGEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 0.5 cm layer of PluroGel® followed by the above standard dressing. In addition, this will be covered with moistened gauze, kept moist twice daily. (The additional factors are the use of PluroGel® and moistened gauze. Standard dressing will continue to be used.)
Trial: NCT05000983
Drug: Standard dressing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antibiotic ointment (Polysporin™ or formulary equivalent) and non-adherent petrolatum fine-meshed gauze (ADAPTIC™) applied every Monday, Wednesday and Friday (or equivalent).
Trial: NCT05204836
Drug: Zoledronic Acid Injection
RxNorm normalized name: zoledronic acid Injection
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5 mg / 100 mL intravenous infusion
Trial: NCT05204836
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL intravenous infusion
Trial: NCT04220008
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05173090
Drug: Ropivacaïne 0,5% for appendectomy or cholecystectomy surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visual analog scale 15 min after arrival in the recovery room, then H+4, H+6, H+12, H+24 and one week after the operation
Trial: NCT06547736
Drug: SHR-A2102 or/and HRS-4642
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: SHR-A2102 SHR-A2102 will be administrated per dose level in which the patients are assigned.~Drug: HRS-4642 HRS-4642 will be administrated per dose level in which the patients are assigned.
Trial: NCT06547736
Drug: SHR-A1811 or/and HRS-4642
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: SHR-A1811 SHR-A1811 will be administrated per dose level in which the patients are assigned.~Drug: HRS-4642 HRS-4642 will be administrated per dose level in which the patients are assigned.
Trial: NCT05074056
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: We will administer intraoperative ketorlac.
Trial: NCT04836533
Drug: Experimental: Open-label antidepressant treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be assigned to open-label or placebo-controlled antidepressant treatment for 8 weeks.
Trial: NCT06084364
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarticular injection with saline
Trial: NCT05448456
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of 0.9% normal saline
Trial: NCT05009901
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo one tablet daily for 8 weeks
Trial: NCT05600075
Drug: microneedling with topical human insulin solution.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 patients will be subjected to microneedling with topical human insulin solution. Selected patients will receive one session of microneedling combined with a topical agent, with two weeks interval till complete clearance or up to 6 sessions.
Trial: NCT06040541
Drug: RMC-9805
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablets
Trial: NCT06040541
Drug: RMC-6236
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablets
Trial: NCT05036135
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered via dry powder inhalation
Trial: NCT05063201
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will attend two visits per week during the 8-week Outpatient Treatment Phase. Counseling services, in the form of Medication Management (MM) will be provided weekly. A urine sample for drug testing, vitals, AEs, and COWS will be collected/assessed at each visit. At the first weekly visit attended, concomitant medications, medication compliance, AIMS and a blood sample for later analysis of plasma levels of cariprazine and its metabolites will also be collected. The TLFB, C-SSRS, CSSA, SOWS, BSCS, DTS and a UPT (females only) will be collected once weekly. On the final appointment of week 8 only, a physical exam and ECG will be performed and standard laboratory measures (blood chemistry, CBC with differential, fasting glucose and lipids, serum prolactin, medical urinalysis) will be assessed. During week 8, additional assessments will be collected, including the ASI, HAM A/D and Treatment Opinion Form (TOF).
Trial: NCT05221892
Drug: Gamma-aminobutyric acid tartarate, glutamic acid, dibasic calcium phosphate, thiamine nitrate, pyridoxine chloride and cyanocobalamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets to be taken 30 minutes before each of 4 trips.
Trial: NCT06214403
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcrystalline Cellulose
Trial: NCT05247203
Drug: standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A standard regimen consists of the following medication(s) (alone or in combination)：corticosteroids, anti-malarials, non-steroidal anti-inflammatory drugs (NSAIDs), other immunosuppressive or immunomodulatory agents including azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, tacrolimus, cyclosporine.
Trial: NCT04778592
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06701305
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injectable solution
Trial: NCT06701305
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution
Trial: NCT05757531
Drug: [¹⁴C]-LY3437943
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT05357040
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60-minute sessions of inhaled oxygen-air mixture (FiO2 ≈0.3) to be administered weekly for 4-weeks.~Administration will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
Trial: NCT05162586
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matched to Enpatoran up to 24 weeks.
Trial: NCT05886478
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As this is an observational study, no intervention will be administered.
Trial: NCT04863794
Drug: RO7248824
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 10 mg RO7248824 will be used for this PET study in healthy participants.
Trial: NCT06050980
Drug: HSK40118
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration, QD
Trial: NCT04927221
Drug: DC371739 Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received one of 5 dose levels of DC371739 administered as single oral doses.
Trial: NCT04927221
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally administered as comparison
Trial: NCT05587283
Drug: Experimental: Low dose LABTHERA-001 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose LABTHERA-001 capsule, 0.2 x 10\^9 CFU/capsule with excipients.
Trial: NCT05587283
Drug: Experimental: Medium dose LABTHERA-001 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose LABTHERA-001 capsule, 1 x 10\^9 CFU/capsule with excipients.
Trial: NCT04713189
Drug: Inhaled fentanyl aerosol
RxNorm normalized name: fentanyl Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the stage I were randomized to 6 BTP episodes, in which 4 BTP episodes were treated with inhale fentanyl aerosol (with a starting dose of 25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25 µg) and 2 BTP episodes with placebo(0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
Trial: NCT04713189
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the stage Ⅰ were randomized to 6 BTP episodes, in which 2 BTP episodes were treated with placebo (0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence. I
Trial: NCT05124912
Drug: Steroid Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best medical management with steroid therapy
Trial: NCT04678154
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the control group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection.
Trial: NCT04678154
Drug: Vancomycin and Tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The patients in the SEXTANT cohort will have 1000 mg of Vancomycin and 1200 mg of Tobramycin administered to the wound surface, fracture site and exposed hardware (if any) just prior to suture closure of the wound or flap. The SEXTANT cohort will then receive at least 72 hours of systemic antibiotic therapy targeted to the modern wound bioburden.
Trial: NCT05558969
Drug: pregnant women taking magnesium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient group who received magnesium as a 4-6 g loading and 2-3 g/h maintenance dose to prevent convulsions in preeclampsia. Pregnant will be operated under general anesthesia. Sugammadex 4mg/kg will be administered when TOF 0 response is seen at the end of surgery. The time from TOF 0 to TOF 0.9 will be recorded. Magnesium and calcium levels in the blood will be studied.
Trial: NCT05558969
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregnant women who do not receive magnesium therapy and who will be operated under general anesthesia. Sugammadex 4mg/kg will be administered when TOF 0 response is seen at the end of surgery. The time from TOF 0 to TOF 0.9 will be recorded. Magnesium and calcium levels in the blood will be studied.
Trial: NCT05150626
Drug: DBPR108 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: DBPR108, tablets, oral
Trial: NCT06171061
Drug: Yangxinshi tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In addition to basic medication, the experimental group will be given Yangxinshi (three tablets each time, three times a day);The treatment period is 24 weeks.
Trial: NCT04749914
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally.
Trial: NCT04971577
Drug: Simvastatin 40mg
RxNorm normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: participants will receive a capsule containing 4 tablets simvastatin 10 mg (40 mg total) every 24 hours at night
Trial: NCT06037564
Drug: DOR/DTG/3TC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doravirine 100 mg (Pifeltro®) will be administered once daily in combination with co-formulated dolutegravir/lamivudine 50/300 mg (Dovato®) for a duration of 48 weeks.
Trial: NCT06715319
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a day (QD) by mouth (PO)
Trial: NCT06717204
Drug: Prescription Drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment only
Trial: NCT05431595
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by Vein (IV)
Trial: NCT06225115
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, oral tablet
Trial: NCT04893863
Drug: Standard dressing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antibiotic ointment (Polysporin™ or formulary equivalent) and non-adherent petrolatum fine-meshed gauze (ADAPTIC™) applied every Monday, Wednesday and Friday (or equivalent).
Trial: NCT04893863
Drug: PluroGel
RxNorm normalized name: PLUROGEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 0.5 cm layer of PluroGel® followed by the above standard dressing. In addition, this will be covered with moistened gauze, kept moist twice daily. (The additional factors are the use of PluroGel® and moistened gauze. Standard dressing will continue to be used.)
Trial: NCT04868292
Drug: SPR206
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three 100 mg SPR206 intravenous doses administered every 8 hours
Trial: NCT04971928
Drug: GSK3228836
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3228836 will be administered
Trial: NCT06102395
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil 750 mg/m\^2, IV, day 1-5 of Q3W
Trial: NCT04844125
Drug: SHR-1209 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1209 Placebo
Trial: NCT05003453
Drug: 1.5% Palmitoylethanolamide (PEA) sold as Levagen+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A topical cream containing 1.5% PEA applied to the affected site 2-times daily, liberally to coat and cover affected area.
Trial: NCT05003453
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A comparator placebo topical moisturiser cream (an unscented moisturising base cream) applied to the affected site 2 times daily, liberally to coat and cover affected area.
Trial: NCT05013554
Drug: SAR443216 IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Powder for solution; Route of administration: IV infusion
Trial: NCT05013554
Drug: SAR443216 SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Powder for solution; Route of administration: SC injection
Trial: NCT06415487
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lymphodepleting agent
Trial: NCT06415487
Drug: ACE2016
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic gamma delta T (gdT) cell therapy
Trial: NCT04206761
Drug: QVM149
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QVM149 is an investigational drug consisting of 150μg indacaterol acetate, 50μg glycopyrronium bromide and 160μg mometasone furoate. The drug is delivered as powder in hard capsules via Breezhaler, a breath-activated device which will deliver a specific dose of medication
Trial: NCT06629389
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The following dose regime for the 4 treatment arms will be used:~DOSE TITRATION PERIOD:~First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The first 7 days dose will be reduced to 0.5 mL/day; on subsequent 7 days, dose will be reduced to 0.3 mL/day. If a patient has reached a maximum tolerated dose, dose reduction will be made at the discretion of the investigator.
Trial: NCT06718751
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO administration of placebo tablet
Trial: NCT06701721
Drug: THN391 MAD
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Route of administration- IVT injection
Trial: NCT05188638
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile isotonic saline
Trial: NCT06102655
Drug: Jiajian Guishen Formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jiajian Guishen Formulation is a formulation of Traditional Chinese Medicine.POI patients will be treat with Jiajian Guishen Formulation for three menstrual cycles; their blood samples are collected before and after treatment.No drug will be used in control group, and their blood samples are collected when join the experiment.
Trial: NCT05710887
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of the placebo (oxygen-air mixture \[FiO2 ≈0.3\]), will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
Trial: NCT05889286
Drug: [F-18]MHF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following intravenous injection of 10 ± 2 mCi (370 ± 74 MBq) \[F-18\]MHF as a bolus, dynamic PET imaging of the lower limbs will be acquired for approximately 90 minutes. The acquired images will be processed. The uptake pattern of \[F-18\]MHF around infected orthopedic knee implant will be determined and compared with its uptake pattern around non-infected knee implants.
Trial: NCT04662164
Drug: hepalatide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 different dosage will be given sequentially to T2D patients
Trial: NCT04660760
Drug: Trifluridine and Tipiracil Hydrochloride
RxNorm normalized name: tipiracil / trifluridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05233124
Drug: Acetylsalicylic acid 100mg
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid 100mg
Trial: NCT04887532
Drug: HR19042 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: phase 1 :8mg; phase 2:12mg; phase 3:16mg
Trial: NCT04141319
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30ml of local infiltration solution containing 60mg ropivacaine
Trial: NCT04141319
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30ml of local infiltration solution containing 0.1mg epinephrine
Trial: NCT05958589
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On the day of operation all patients will recieve midazolam 0.5 mg/kg (maximum dose 15 mg) orally. Induction of anesthesia will be the same for all patients and consist of intravenous anesthetic propofol (2-3 mg/kg), opioid analgesic fentanyl (1-1.5 mcg/kg), and muscle relaxant rocuronium - bromide (0.6-1 mg/kg). The airway will be obtained by placing a laryngeal mask (I-gel®).
Trial: NCT05942716
Drug: Administration of a PET radiotracer
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A highly selective 5-HT2A receptor ligand (\[18F\]-altanserin) will be injected to patients before each PET scan. The IV injection in the arm (via a catheter) will be performed in continue during a period of 2 hours in the imaging centre (CERMEP) before the acquisition. The dose will be 2,6 MBq/kg +/- 10 % depending the prescription of the nuclear medicine.~Patients will be evaluated twice, one time free of neuroleptic treatment and a second time during stable chronic treatment by neuroleptic.
Trial: NCT04516603
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no active component
Trial: NCT05261711
Drug: AB1
RxNorm normalized name: Hb 19(AB1), Ala-glu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This will be an open-label, dose escalating study with a starting dose of 2mg. Up to 6 additional cohorts will be enrolled at subsequently higher doses of 4mg, 8mg, 10 mg, 12 mg, 16mg, and 32mg. Each dose will be taken orally, once daily, for 8 weeks
Trial: NCT06163326
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching capsule once daily
Trial: NCT04678401
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intravenously with Mesna on day -8 and day- 7 prior to hematopoietic stem cell transplant (HSCT)
Trial: NCT05196308
Drug: Investigational product administration Xeomin® (MERZ PHARMACEUTICALS GMBH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of the investigational product.~For the double-blind treatment phase, experimental group :~Patients will receive Xeomin® (MERZ PHARMACEUTICALS GMBH), 100 U, a paired intracavernosal injection to be performed by the investigator.
Trial: NCT05196308
Drug: Placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the double-blind treatment phase, control group :~Patients will receive placebo of Xeomin® 100 U, a paired intracavernosal injection is to be performed by the investigator.
Trial: NCT04886050
Drug: LC350189 Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will receive an LC350189 Tablet as single dose on Day 1 or Day 5
Trial: NCT04886050
Drug: LC350189 Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will receive an LC350189 Capsule as single dose on Day 1 or Day 5
Trial: NCT06680921
Drug: SIM0270
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental
Trial: NCT05638828
Drug: RD14-01 Cell injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RD14-01 Cell injection
Trial: NCT04826237
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose to be taken with methylprednisolone
Trial: NCT04826237
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule the same as for statins but without statin